date,title,source
Oct-19-18,MorphoSys's Licensee Janssen has Reported That New Tremfya(R) (Guselkumab) 3-Year Data Shows Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis,ACCESSWIRE
Nov-01-18,MorphoSys to Present Data on Investigational Drugs MOR208 and MOR202 in Various Blood Cancer Indications at ASH 2018 Meeting,ACCESSWIRE
Nov-05-18,DGAP-News: MorphoSys AG Announces Third Quarter 2018 Results,ACCESSWIRE
Nov-15-18,"BRIEF-Morphosys, I-Mab Sign Agreement For Morphosys's Novel Immuno-Oncology Agent MOR210",Reuters
Nov-15-18,MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210,ACCESSWIRE
Nov-16-18,"The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal",Benzinga
Nov-19-18,MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA) to Evaluate Guselkumab in Hidradenitis Suppurativa,ACCESSWIRE
Nov-20-18,"The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings",Benzinga
Nov-21-18,MorphoSys to Present at Upcoming Investor Conferences,ACCESSWIRE
Nov-26-18,MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the Treatment of Patients with Palmoplantar Pustulosis,ACCESSWIRE
Dec-07-18,"MorphoSys Announces that According to a Presentation Title at an Upcoming Conference, Guselkumab Demonstrates Superior Long-Term Responses to Secukinumab at Week 48 in the Treatment of Moderate to Severe Psoriasis",ACCESSWIRE
